Sheller says roughly half a million clinical trials are registered on ClinicalTrials.gov.
“I think there's a half a million clinical trials registered at clintrials.gov. And so it's just, it's exploded.”
Person
Jennifer Sheller is a Merck clinical operations leader who spoke on the Business Of Biotech podcast about modernizing how clinical trials are run, including outsourcing models, company acquisitions, trial rules and the use of AI. She said she spent about 13 years at Sanofi, then moved to Kyowa Kirin, and has now been at Merck for over eight years.
Sheller said Merck's clinical operations model uses about 60% of its own staff and about 40% outside provider staff. She also described Merck's integrations of acquired companies, including Peloton Therapeutics, and said Merck is resetting its operating model around risk-based quality management, with implementation planned for 2026. Each fact below is shown with her exact quote and a link to the moment.
1 episodes · 21 quoted claims
Sheller says roughly half a million clinical trials are registered on ClinicalTrials.gov.
“I think there's a half a million clinical trials registered at clintrials.gov. And so it's just, it's exploded.”
In the late 1990s, clinical research associates verified hospital records against handwritten triple-copy NCR paper forms, which later gave way to electronic data capture.
“when I first started in the late 90s, it was, you know, triple NCR paper. So we'd go out to the hospitals to make sure that the records in the hospital system matched what was handwritten on an NCR form.”
Sheller spent about 13 years at Sanofi, then moved to the biotech Kyowa Kirin, and has now been at Merck for over eight years.
“I spent about 13 years at large pharma at Sanofi and went to a small biotech, Keowakirin, shortly thereafter, before coming back into large pharma here at Merck for over eight years.”
Andy Lee, a former Sanofi colleague of Sheller, moved Merck from a fully outsourced clinical operations model to an in-house one.
“So he came into Merck and really shifted the paradigm from outsourced, fully outsourced model to bringing everything in-house.”
Merck's clinical operations model uses about 60% of its own headcount and about 40% functional service provider staff.
“So he brought everything in-house and built an operating model where we have, you know, 60% headcount through our company and then 40% or so through functional service provider.”
Sheller says unit-priced outsourcing contracts fit poorly because a safety signal can require extra monitoring, forcing change orders.
“if you have unitized pricing for a given study, X number of monitoring visits, X number of phone calls to a site, that's not the real world because you might have a safety signal where you need extra monitoring.”
Merck received its first approval for a product from Peloton Therapeutics within two years of acquiring the company.
“I'll share the Peloton example that came forward with a product that we got our first approval within two years of acquiring Peloton.”
Merck acquired a HIF2-alpha inhibitor from Peloton Therapeutics, with VHL-associated renal cell carcinoma as its first indication.
“we brought in the HIF2-alpha inhibitor from Peloton and renal cell carcinoma and VHL was our first indication.”
Sheller says the Acceleron acquisition, with a large phase three program, was probably Merck's most challenging integration.
“Accelerant had a large phase three program that was probably the most challenging integration.”
During the Peloton integration, Sheller hired a summer intern to shadow the team and write the integration playbook that became Merck's operations standard.
“I actually hired one of my summer interns to extend her stay for a project to shadow us and build the playbook out.”
Sheller cites Merck's Prometheus acquisition as a return to immunology, an area Merck had not been in for a while.
“That was an area we haven't been in in a while with the Prometheus acquisition, for example.”
Sheller cites a study saying data collection in clinical trials has risen more than threefold over roughly the last decade.
“over the last decade or so, I think they quoted that we've increased data collection in trials more than threefold.”
The ICH good clinical practice guideline dates from 1996 and has now reached its third revision.
“this is, I think, from 1996, so revision three, and it's taken that long of time.”
Sheller says revision three of ICH good clinical practice makes risk proportionality a principle, applying more rigor to critical data and processes.
“Meaning, you don't treat all of your data the same. You focus on critical data, critical data and processes with a higher amount of rigor.”
A TransCelerate study found only about 2-3% of critical data changed as a result of 100% source data verification.
“they showed only like two to 3% of critical data changed from all of that effort doing that cross check.”
Sheller says Merck wants to use AI and natural language processing to trend non-important protocol deviations so teams can focus on serious ones.
“that's where AI can help me trend the non-important deviations for the oversight.”
Some research sites told Merck they would not run a trial unless non-physician sub-investigators, such as nurse practitioners, were allowed under the R3 changes, and Merck changed its process.
“hey, look, we're not going to do this trial unless you do apply the R3 changes and having non-physician investigators or sub-investigators in the trial.”
Sheller says about 5% to 8% of US cancer patients participate in a clinical trial.
“I think is 5 % to 8 % of cancer patients participate in a clinical trial, whereas many would be interested if they were asked.”
Merck created the Let's Talk Trials education campaign for the whole clinical research industry rather than for Merck alone.
“Let's Talk Trials is something that we created for the industry, for clinical research as a whole. It's not specific to Merck.”
Sheller says Merck is resetting its operating model around risk-based quality management, with implementation planned for 2026.
“we're really focused, as I mentioned earlier, on resetting our operating model with risk-based quality management.”
Sheller says she has built an automation hub at Merck, linked to the organization's functions through matrix leads.
“So I build an automation hub and I'm pairing it up through the functions in our organization.”